Bevacizumab: all 1,786 studies that test it

Page 4 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.

• Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)TerminatedNCT04541173Phase 2Results posted
• A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersCompletedNCT04516278Phase 3Results posted
• Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsTerminatedNCT04512430Phase 2Results posted
• A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-AmethistaCompletedNCT04487067Phase 3Results posted
• Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)CompletedNCT04456699Phase 3Results posted
• A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerCompletedNCT04426825Phase 2Results posted
• A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLCTerminatedNCT04325698Phase 3Results posted
• Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male VolunteersCompletedNCT04238663Phase 1Results posted
• A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male VolunteersCompletedNCT04238650Phase 1Results posted
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyCompletedNCT04109924Phase 2Results posted
• A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Phase 3Results posted
• Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibTerminatedNCT04099836Phase 2Results posted
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT04094688Phase 3Results posted
• Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaCompletedNCT04091217Phase 2Results posted
• A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesCompletedNCT04042558Phase 2Results posted
• A Phase I Study Comparing Pharmacokinetics and Safety of BevacizumabCompletedNCT03919448Phase 1Results posted
• A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03834753Phase 3Results posted
• Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationCompletedNCT03829410Phase 1/2Results posted
• Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03713944Phase 2Results posted
• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedNCT03694262Phase 2Results posted
• To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung CancerCompletedNCT03676192Phase 3Results posted
• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent GlioblastomaCompletedNCT03661723Phase 2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03635489Phase 3Results posted
• QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedNCT03586869Phase 1/2Results posted
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedNCT03555149Phase 1/2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumCompletedNCT03476798Phase 2Results posted
• Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerCompletedNCT03475004Phase 2Results posted
• Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed GlioblastomaCompletedNCT03463265Phase 2Results posted
• Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMActive, not recruitingNCT03452579Phase 2Results posted
• A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Phase 3Results posted
• A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer TreatmentCompletedNCT03428958Phase 1/2Results posted
• Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal CancerCompletedNCT03396926Phase 2Results posted
• To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male SubjectsCompletedNCT03390673Phase 1Results posted
• QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedNCT03387111Phase 1/2Results posted
• QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03387098Phase 1/2Results posted
• QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedNCT03387085Phase 1/2Results posted
• Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical CancerTerminatedNCT03367871Phase 2Results posted
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
• A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung CancerCompletedNCT03329911Phase 3Results posted
• QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03329248Phase 1/2Results posted
• A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyCompletedNCT03326193Phase 2Results posted
• DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DMECompletedNCT03321513Phase 3Results posted
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results posted
• A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03296163Phase 3Results posted
• A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male VolunteersCompletedNCT03293654Phase 1Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results posted
• Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerTerminatedNCT03272217Phase 2Results posted
• To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed AvastinCompletedNCT03247673Phase 1Results posted
• Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTACompletedNCT03246152Phase 4Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedNCT03193190Phase 1/2Results posted
• QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03136406Phase 1/2Results posted
• Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MCompletedNCT03133546Phase 2Results posted
• Evaluation of Weekly Ixabepilone With or Without Biweekly BevacizumabCompletedNCT03093155Phase 2Results posted
• Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy MaleCompletedNCT03083990Phase 1Results posted
• TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade AstrocytomaCompletedNCT03032484Phase 2Results posted
• Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell CarcinomaTerminatedNCT03024437Phase 1/2Results posted
• Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell TumorsTerminatedNCT02988843Phase 2Results posted
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results posted
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive, not recruitingNCT02971501Phase 2Results posted
• Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLCCompletedNCT02954172Phase 3Results posted
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical CancerCompletedNCT02921269Phase 2Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal CancerTerminatedNCT02842580Phase 2Results posted
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02839707Phase 2/3Results posted
• Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)CompletedNCT02819479Phase 2Results posted
• Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung CancerCompletedNCT02810457Phase 3Results posted
• Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersCompletedNCT02803203Phase 1/2Results posted
• Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal CancerCompletedNCT02776683Phase 3Results posted
• A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive TherapyCompletedNCT02743221Phase 2Results posted
• Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent GlioblastomaTerminatedNCT02743078Phase 2Results posted
• Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaCompletedNCT02724878Phase 2Results posted
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)CompletedNCT02681549Phase 2Results posted
• Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)TerminatedNCT02664961Phase 2Results posted
• TTFields and Pulsed Bevacizumab for Recurrent GlioblastomaTerminatedNCT02663271Phase 2Results posted
• Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal CancerTerminatedNCT02654639Phase 2Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or RectumCompletedNCT02582970Phase 4Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results posted
• Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain MetastasesTerminatedNCT02490878Phase 2Results posted
• Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular EdemaCompletedNCT02471651Phase 4Results posted
• Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot InitiativeCompletedNCT02456857Phase 2Results posted
• A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)CompletedNCT02420821Phase 3Results posted
• TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory ChoriocarcinomaCompletedNCT02396511Phase 2Results posted
• Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCCompletedNCT02394795Phase 3Results posted
• Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of PrematurityCompletedNCT02390531Phase 1Results posted
• Intranasal Bevacizumab for HHT-Related EpistaxisCompletedNCT02389959Phase 4Results posted
• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02366143Phase 3Results posted
• Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular EdemaCompletedNCT02348918Phase 2Results posted
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:CompletedNCT02348008Phase 1/2Results posted
• A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)TerminatedNCT02343549Phase 2Results posted
• TH-302 in Combination With Bevacizumab for GlioblastomaCompletedNCT02342379Phase 2Results posted
• Pembrolizumab +/- Bevacizumab for Recurrent GBMCompletedNCT02337491Phase 2Results posted
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCompletedNCT02330562Phase 1/2Results posted
• Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade GliomasCompletedNCT02313272Phase 1Results posted
• Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02312245Phase 2Results posted

← Bevacizumab overview